Roivant Sciences (ROIV) Director James C. Momtazee Receives Award

What Happened
James C. Momtazee, a director of Roivant Sciences Ltd. (ROIV), was reported as receiving an award of 405 common shares on July 17, 2026. The Form 4 lists the transaction as an award/acquisition (code A) at $0.00 per share (total recorded acquisition value $0). The filing’s footnote states the shares were issued under the Issuer’s Non‑Employee Director Compensation Plan and were fully vested as of the grant date. This was an award (compensation), not a purchase or sale.

Key Details

• Transaction date: July 17, 2026; Transaction type: Award (code A)
• Shares acquired: 405 common shares; Price reported: $0.00; Total recorded value: $0
• Shares owned after transaction: not disclosed in this filing
• Footnote: F1 — award pursuant to Non‑Employee Director Compensation Plan; fully vested on grant date
• Filing date: July 21, 2026 (filed 4 days after the transaction date, including weekend). Form 4s are generally due within 2 business days; this filing appears to have been submitted after that typical window.
• Exhibit: Exhibit 24 — Power of Attorney

Context
Director equity awards are a common component of non‑employee director compensation and often reflect routine pay rather than a trading decision. Because the award was fully vested at grant, no future service-based vesting was required. The $0 acquisition price on the Form 4 reflects that these were shares issued as compensation; it does not show market value or a cash payment. For investors tracking insider signals, outright purchases of stock tend to be more directly indicative of bullishness than routine compensation awards.